-
FDA Supports Continued Development of Eftilagimod Alfa in PD-L1–Negative Head and Neck Cancer
07 Aug 2025 03:47 GMT
… line treatment of metastatic or recurrent HNSCC.2
The … of efti and Keytruda or Keytruda alone.
Patients in … to forward paths in head and neck cancer.”
Combination outperforms monotherapy in … in Patients With Recurrent or Metastatic HNSCC (TACTI-003 …
-
Eftilagimod Alfa Demonstrates Potential in PD-L1–Low Head and Neck Cancer
06 Aug 2025 21:48 GMT
… patients with unresectable recurrent or metastatic HNSCC.3 One … randomized efti plus pembrolizumab or pembrolizumab alone.
The study … of Eftilagimod Alfa in Head and Neck Cancer with CPS <1 … in Patients With Recurrent or Metastatic HNSCC (TACTI-003 …
-
Thyroid Dysfunction Common After Radiotherapy in Head and Neck Cancer Patients, Study Warns
06 Aug 2025 17:24 GMT
Brazil: A recent study published in Head & Neck highlights the increased risk of thyroid dysfunction in patients with head and neck squamous cell carcinoma (HNSCC) following external radiotherapy (RT). The study found that more than half (54.7%) of …
-
Why is the Lack of Head and Neck Cancer Awareness a Growing Health Concern in India?
06 Aug 2025 11:50 GMT
Head and neck cancer awareness is a growing health concern in India
Head and neck cancers exhibit a … decreased mouth opening, swelling or lumps in the neck, pain … such cancers.
Treatment for head and neck cancer typically involves a multidisciplinary approach …
-
Immutep Receives Positive Feedback from FDA on Late-Stage Clinical Development of Eftilagimod Alfa in Head and Neck Cancer with CPS <1
05 Aug 2025 12:00 GMT
… IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage … standard-of-care therapy or alternatively a smaller single … regards to forward paths in head and neck cancer,” added Mr Voigt. … prior lines of therapies or have exhausted available treatment …
-
Rowan University and Sentrimed Announce Phase 1 Clinical Trial Results Demonstrating Potential of MASL to Inhibit Oral Cancer Cell Migration and Viability
07 Aug 2025 06:21 GMT
… for the treatment of head and neck cancers, with expansion potential … regarding our future financial or business performance, plans, … results, performance or achievements expressed or implied by the … . No representations or warranties (expressed or implied) are …
-
Luxel Corporation Appoints Adrian Polliack, Phd, As President
07 Aug 2025 05:11 GMT
… developing an oral device for head and neck cancer radiotherapy, and Diatomix, a specialty … do not accept
any responsibility or liability for the accuracy, content … images,
videos, licenses, completeness, legality, or reliability of the information
contained …
-
International Leader in Radiation Oncology Appointed Chair to Lead Efforts Across Multiple Rutgers Campuses and at New Jersey's Only National Cancer Institute-Designated
Comprehensive Cancer Center
07 Aug 2025 00:03 GMT
… has served as principal investigator or co-investigator on over 20 … a member of the NCI Head and Neck Cancer Steering Committee.
“Dr. Contessa’s …
-
International Leader in Radiation Oncology Appointed Chair to Lead Efforts Across Multiple Rutgers Campuses and at New Jersey’s Only National Cancer Institute-Designated Comprehensive Cancer Center
06 Aug 2025 23:36 GMT
… has served as principal investigator or co-investigator on over 20 … a member of the NCI Head and Neck Cancer Steering Committee.
“Dr. Contessa’s …
-
Press release from hospital district: ENT service expanding here
06 Aug 2025 21:36 GMT
… infections to complex conditions like head and neck cancers. It also provides dedicated pediatric … neck lesions on a weekly or bi-weekly basis. Significantly, for … by calling (985) 384-9440 or online at https:/…
About
© 1995-2025